Suggested remit - To appraise the clinical and cost effectiveness of galcanezumab within its marketing authorisation for preventing cluster headache.
 
Status Proposed
Process STA 2018
ID number 1212

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 November 2018 - 11 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance